Evidence map›Paper›PMID 34100014›Full record

ArticlebioRxiv : the preprint server for biology2021

Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.

Alex J B Kreutzberger, Anwesha Sanyal, Ravi Ojha, Jesse D Pyle, Olli Vapalahti, Giuseppe Balistreri, Tom Kirchhausen

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alex J B KreutzbergerDepartment of Cell Biology, Harvard Medical School, 200 Longwood Av, Boston, MA 02115, USA.
Anwesha SanyalDepartment of Cell Biology, Harvard Medical School, 200 Longwood Av, Boston, MA 02115, USA.
Ravi OjhaDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jesse D PyleProgram in Virology, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115, USA.
Olli VapalahtiDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Giuseppe BalistreriDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Tom KirchhausenDepartment of Cell Biology, Harvard Medical School, 200 Longwood Av, Boston, MA 02115, USA.
Boston Children's Hospital · USUniversity of Helsinki · FIHarvard University · US

Funding

Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
Neuro HPA Project 1U54AG062334 · NIA · EMORY UNIVERSITY · PI Ighovwerha Ofotokun · 2018 to 2026
$12.2M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
VISUALIZATION OF SUBCELLULAR DYNAMICS IN MULTICELLULAR ORGANISMSR35GM130386 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI TOMAS KIRCHHAUSEN · 2019 to 2026
$4.0M
Emory R38 Research Training ProgramR38AI140299 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, ROUPHAEL, NADINE GEORGES · 2018 to 2021
$1.4M
NIAID NIH HHS R38 AI140299NIAID NIH HHS T32 AI007245NIAID NIH HHS U01 AI103408NIA NIH HHS U54 AG062334NIGMS NIH HHS R35 GM130386
6 · The paper itself

Abstract

Repurposing FDA-approved inhibitors able to prevent infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could provide a rapid path to establish new therapeutic options to mitigate the effects of coronavirus disease 2019 (COVID-19). Proteolytic cleavages of the spike S protein of SARS-CoV-2, mediated by the host cell proteases cathepsin and TMPRSS2, alone or in combination, are key early activation steps required for efficient infection. The PIKfyve kinase inhibitor apilimod interferes with late endosomal viral traffic, and through an ill-defined mechanism prevents

Identifiers

PMID34100014
PMCPMC8183009
OpenAlexW3188132545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.